Sol-Gel Technologies (SLGL) Corporate presentation summary

Management and leadership

• Executive team includes CEO/Chairman, CFO, Chief Business Officer, VP Clinical and Regulatory Affairs, COO, and VP R&D.

Pipeline and clinical focus

• Pipeline targets skin diseases with no approved therapeutics, including Gorlin syndrome and high-frequency BCC.

• SGT-610 (patidegib gel 2%) is in Phase 3 for Gorlin syndrome and high-frequency BCC, with top-line results expected Q4 2026.

• SGT-210 (topical erlotinib) is advancing to proof-of-concept studies in H2 2026.

• Commercial products include TWYNEO for acne and EPSOLAY for rosacea.

SGT-610: Patidegib gel for Gorlin syndrome and high-frequency BCC

• Gorlin syndrome is a rare disorder causing multiple early-onset BCCs, affecting ~11,000 in the US.

• No approved preventive treatments exist; patients often undergo repeated surgeries.

• SGT-610 inhibits the Hedgehog pathway locally, aiming to prevent new BCCs.

• Received Orphan Drug and Breakthrough Therapy designations in the US and EU.

• Market opportunity estimated at over $600M if approved.